Antibody Drug Conjugates Contract Manufacturing Market Size and Share 2034

Antibody Drug Conjugates Contract Manufacturing Market Size- By Linker, By Condition- Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Q: How can I get a sample report on the Antibody Drug Conjugates Contract Manufacturing Market?

You can get the sample pages by clicking the link - Click Here

Published: Sep-2025	Report ID: HLCA25271	Pages: 1 - 242	Formats^*:
Category : Healthcare

Antibody Drug Conjugates Contract Manufacturing Market Introduction and Overview

According to SPER Market Research, the Global Antibody Drug Conjugates Contract Manufacturing Market is estimated to reach USD 25762.76 million by 2034 with a CAGR of 11.25%.

The report includes an in-depth analysis of the Global Antibody Drug Conjugates Contract Manufacturing Market, including market size and trends, product mix, Applications, and supplier analysis. The Global Antibody Drug Conjugates Contract Manufacturing market was valued at USD 8871.4 million in 2024 and is projected to increase at a compound annual growth rate (CAGR) of 11.25% between 2025 and 2034. The industry is expected to experience substantial growth in the coming years, driven by the increasing prevalence of cancer, the rising demand for biologic therapies, and the complexities involved in antibody-drug conjugate (ADC) manufacturing, which are fueling the need for contract manufacturing services.

By Linker Insights:

Cleavable linkers dominate the market as they enable precise drug release within cancer cells, improving potency while limiting side effects. Advancements in linker technology and rising ADC approvals are driving demand for CMOs skilled in scalable, high-purity linker production. The non-cleavable linker segment is growing quickly due to its role in safer, longer-lasting next-generation ADCs. Innovation in linker design and increased ADC investments are prompting CMOs to enhance capabilities for producing scalable, high-quality linker-payload combinations.

By Condition Insights:

The myeloma segment leads the market, driven by growing adoption of BCMA-targeting ADCs and a strong clinical pipeline. Regulatory support and advances in linker-payload technologies have increased reliance on CMOs with expertise in bioconjugation, high-potency API handling, and scalable manufacturing to meet treatment demand.

The lymphoma segment is set for the fastest growth due to rising demand for targeted ADC therapies with better efficacy and fewer side effects. Pharmaceutical and biotech investments in lymphoma-focused ADC development are boosting the need for CMOs with advanced, scalable production capabilities.

Regional Insights:

The antibody drug conjugates contract manufacturing market in North America is growing rapidly due to increased outsourcing by U.S. pharmaceutical companies seeking faster market entry and cost savings. The region benefits from advanced manufacturing technologies like site-specific conjugation and high-yield processes, which enable efficient, scalable production. Strong regulatory support from the U.S. FDA and growing collaborations and acquisitions among industry players further fuel market growth.

Get more information on this report: Download Free Sample PDF

Market Competitive Landscape:

Leading Companies are known for their advanced biopharmaceutical manufacturing capabilities, providing end-to-end services from early development to large-scale ADC production. Key players are pursuing strategic moves like acquisitions, partnerships, expansions, agreements, and collaborations to strengthen their market presence and gain a competitive advantage, thereby fueling market growth. Some key players are- Sterling; Recipharm AB; Lonza; Catalent, Inc.; Sartorius AG; Wuxi Biologics; Samsung Biologics; Piramal Group (Piramal Pharma Solutions); AbbVie, Inc. (AbbVie Contract Manufacturing); and Merck KGaA.

Recent Developments:

In May 2024, Wuxi AppTec, Inc. expanded its operations by opening a new R&D and manufacturing facility in Singapore, offering API R&D and manufacturing services for peptides, small molecules, complex synthetic conjugates, and oligonucleotides.

In December 2023, Piramal Pharma Solutions expanded its ADC manufacturing facility in Grangemouth, Scotland, boosting production capacity by 70â€“80% and enhancing its ability to support more customers throughout the drug development lifecycle.

Scope of the report:

Report Metric	Details
Market size available for years	2021-2034
Base year considered	2024
Forecast period	2025-2034
Segments covered	By Linker, By Condition
Regions covered	North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered	Sterling; Recipharm AB; Lonza; Catalent, Inc.; Sartorius AG; Wuxi Biologics; Samsung Biologics; Piramal Group (Piramal Pharma Solutions); AbbVie, Inc. (AbbVie Contract Manufacturing); and Merck KGaA.

Key Topics Covered in the Report:

Global Antibody Drug Conjugates Contract Manufacturing Market Size (FY 2021-FY 2034)

Overview of Global Antibody Drug Conjugates Contract Manufacturing Market

Segmentation of Global Antibody Drug Conjugates Contract Manufacturing Market By Linker (Myeloma, Lymphoma, Breast Cancer, Others)

Segmentation of Global Antibody Drug Conjugates Contract Manufacturing Market By Condition (Cleavable Linker, Non-cleavable Linker)

Statistical Snap of Global Antibody Drug Conjugates Contract Manufacturing Market

Expansion Analysis of Global Antibody Drug Conjugates Contract Manufacturing Market

Problems and Obstacles in Global Antibody Drug Conjugates Contract Manufacturing Market

Competitive Landscape in the Global Antibody Drug Conjugates Contract Manufacturing Market

Details on Current Investment in Global Antibody Drug Conjugates Contract Manufacturing Market

Competitive Analysis of Global Antibody Drug Conjugates Contract Manufacturing Market

Prominent Players in the Global Antibody Drug Conjugates Contract Manufacturing Market

SWOT Analysis of Global Antibody Drug Conjugates Contract Manufacturing Market

Global Antibody Drug Conjugates Contract Manufacturing Market Future Outlook and Projections (FY 2025-FY 2034)

Recommendations from Analyst

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source

2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs

2.2. Market size estimation

2.2.1. Top-down and Bottom-up approach

2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis

4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis

5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats

5.2. PESTEL Analysis

5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape

5.3. PORTERs Five Forces

5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry

5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Antibody Drug Conjugates Contract Manufacturing Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Antibody Drug Conjugates Contract Manufacturing Market

7. Global Antibody Drug Conjugates Contract Manufacturing Market, By Linker (USD Million) 2021-2034

7.1. Myeloma
7.2. Lymphoma
7.3. Breast Cancer
7.4. Others

8. Global Antibody Drug Conjugates Contract Manufacturing Market, By Condition (USD Million) 2021-2034

8.1. Cleavable Linker
8.2. Non-cleavable Linker

9. Global Antibody Drug Conjugates Contract Manufacturing Market, (USD Million) 2021-2034

9.1. Global Antibody Drug Conjugates Contract Manufacturing Market Size and Market Share

10. Global Antibody Drug Conjugates Contract Manufacturing Market, By Region, (USD Million) 2021-2034

10.1. Asia-Pacific

10.1.1. Australia
10.1.2. China
10.1.3. India
10.1.4. Japan
10.1.5. South Korea
10.1.6. Rest of Asia-Pacific

10.2. Europe

10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Spain
10.2.5. United Kingdom
10.2.6. Rest of Europe

10.3. Middle East and Africa

10.3.1. Kingdom of Saudi Arabia
10.3.2. United Arab Emirates
10.3.3. Qatar
10.3.4. South Africa
10.3.5. Egypt
10.3.6. Morocco
10.3.7. Nigeria
10.3.8. Rest of Middle-East and Africa

10.4. North America

10.4.1. Canada
10.4.2. Mexico
10.4.3. United States

10.5. Latin America

10.5.1. Argentina
10.5.2. Brazil
10.5.3. Rest of Latin America

11. Company Profile

11.1. Sterling

11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments

11.2. Recipharm AB

11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments

11.3. Lonza

11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments

11.4. Sartorius AG

11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments

11.5. Wuxi Biologics

11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments

11.6. Samsung Biologics

11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments

11.7. Piramal Group (Piramal Pharma Solutions)

11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments

11.8. AbbVie, Inc. (AbbVie Contract Manufacturing)

11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments

11.9. Merck KGaA

11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments

11.10. Catalent, Inc.

11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments

11.11. Others

12. Conclusion

13. List of Abbreviations

14. Reference Links

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3

Frequently Asked Questions About This Report

How big is the Antibody Drug Conjugates Contract Manufacturing Market?

Antibody Drug Conjugates Contract Manufacturing Market is projected to reach USD 25762.76 million by 2034, growing at a CAGR of of 11.25% during the forecast period.

What is the growth rate of the Antibody Drug Conjugates Contract Manufacturing Market?

Antibody Drug Conjugates Contract Manufacturing Market grew in Market size from 2025. The Market is expected to reach USD 25762.76 million by 2034, at a CAGR of 11.25% during the forecast period.

What is the anticipated CAGR of the Antibody Drug Conjugates Contract Manufacturing Market?

Antibody Drug Conjugates Contract Manufacturing Market CAGR of 11.25% during the forecast period.

How can I get a sample report on the Antibody Drug Conjugates Contract Manufacturing Market?

You can get the sample pages by clicking the link - Click Here

What is the Market size of the Antibody Drug Conjugates Contract Manufacturing Market?

Antibody Drug Conjugates Contract Manufacturing Market size is USD 25762.76 millionfrom 2025 to 2034.

Which segment is expected to Antibody Drug Conjugates Contract Manufacturing Market?

Antibody Drug Conjugates Contract Manufacturing Market is covered By Linker, By Condition

Which region is expected to have the highest Market share in the Antibody Drug Conjugates Contract Manufacturing Market?

The North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa is the highest Market share in the Antibody Drug Conjugates Contract Manufacturing Market.

Who are the key players in Antibody Drug Conjugates Contract Manufacturing Market?

Sterling; Recipharm AB; Lonza; Catalent, Inc.; Sartorius AG; Wuxi Biologics; Samsung Biologics; Piramal Group (Piramal Pharma Solutions); AbbVie, Inc. (AbbVie Contract Manufacturing); and Merck KGaA.

What is the conclusion of the Antibody Drug Conjugates Contract Manufacturing Market?

The report includes an in-depth analysis of the Global Antibody Drug Conjugates Contract Manufacturing Market, including market size and trends, product mix, Applications, and supplier analysis.